The July 2026 Pharmacy Compounding Advisory Committee meeting produced the most recent catalyst, with panel members voting 8-6 (one abstention) to recommend BPC-157 for the Section 503A Bulks List despite FDA staff opposition citing immunogenicity and impurity concerns. This non-binding advisory step followed the peptide’s earlier removal from Category 2 restrictions and occurs under current HHS leadership. Final FDA action on formal Category 1 placement remains pending, creating the core uncertainty reflected in trader pricing. Resolution hinges on whether the agency accepts the recommendation and issues the corresponding update to compounding eligibility lists, with any timeline tied to agency rulemaking procedures. Historical patterns show advisory votes are sometimes followed but can be overridden on safety grounds.
Resumen experimental generado por IA con datos de Polymarket. Esto no es asesoramiento de trading y no influye en cómo se resuelve este mercado. · ActualizadoNUEVO
31 ago 2026
31 de agosto de 2026
16%
31 de diciembre de 2026
50%
$2,565 Vol.
31 de agosto de 2026
$859 Vol.
16%
31 de diciembre de 2026
$1,706 Vol.
50%
This market will resolve to “Yes” if the Food and Drug Administration (FDA) announces that it has reclassified or will reclassify BPC-157 to Category 1 of the Bulk Drug Substances List by the listed date, 11:59 PM ET. Otherwise, this market will resolve to “No”.
A qualifying announcement must be official and public. Any rumored or private statements of intention will not qualify.
Any announcement that the drug has been reclassified to Category 1 will qualify. Any announcement within this market’s timeframe of future intention to reclassify to Category 1 will qualify regardless of whether the reclassification has happened by the listed date.
A qualifying reclassification must be to Category 1 of the Bulk Drug Substances List or an equivalent classification that allows interim compounding of the drug. Removal from a different category will not qualify.
The resolution source for this market will be official statements from the FDA; however, a consensus of credible reporting will also be used.The July 2026 Pharmacy Compounding Advisory Committee meeting produced the most recent catalyst, with panel members voting 8-6 (one abstention) to recommend BPC-157 for the Section 503A Bulks List despite FDA staff opposition citing immunogenicity and impurity concerns. This non-binding advisory step followed the peptide’s earlier removal from Category 2 restrictions and occurs under current HHS leadership. Final FDA action on formal Category 1 placement remains pending, creating the core uncertainty reflected in trader pricing. Resolution hinges on whether the agency accepts the recommendation and issues the corresponding update to compounding eligibility lists, with any timeline tied to agency rulemaking procedures. Historical patterns show advisory votes are sometimes followed but can be overridden on safety grounds.
This market will resolve to “Yes” if the Food and Drug Administration (FDA) announces that it has reclassified or will reclassify BPC-157 to Category 1 of the Bulk Drug Substances List by the listed date, 11:59 PM ET. Otherwise, this market will resolve to “No”.
A qualifying announcement must be official and public. Any rumored or private statements of intention will not qualify.
Any announcement that the drug has been reclassified to Category 1 will qualify. Any announcement within this market’s timeframe of future intention to reclassify to Category 1 will qualify regardless of whether the reclassification has happened by the listed date.
A qualifying reclassification must be to Category 1 of the Bulk Drug Substances List or an equivalent classification that allows interim compounding of the drug. Removal from a different category will not qualify.
The resolution source for this market will be official statements from the FDA; however, a consensus of credible reporting will also be used.
A qualifying announcement must be official and public. Any rumored or private statements of intention will not qualify.
Any announcement that the drug has been reclassified to Category 1 will qualify. Any announcement within this market’s timeframe of future intention to reclassify to Category 1 will qualify regardless of whether the reclassification has happened by the listed date.
A qualifying reclassification must be to Category 1 of the Bulk Drug Substances List or an equivalent classification that allows interim compounding of the drug. Removal from a different category will not qualify.
The resolution source for this market will be official statements from the FDA; however, a consensus of credible reporting will also be used.
Mercado abierto: Jun 22, 2026, 10:10 PM ET
Volumen
$2,565Fecha de finalización
31 dic 2026Mercado abierto
Jun 22, 2026, 10:10 PM ETResolver
0x65070BE91...This market will resolve to “Yes” if the Food and Drug Administration (FDA) announces that it has reclassified or will reclassify BPC-157 to Category 1 of the Bulk Drug Substances List by the listed date, 11:59 PM ET. Otherwise, this market will resolve to “No”.
A qualifying announcement must be official and public. Any rumored or private statements of intention will not qualify.
Any announcement that the drug has been reclassified to Category 1 will qualify. Any announcement within this market’s timeframe of future intention to reclassify to Category 1 will qualify regardless of whether the reclassification has happened by the listed date.
A qualifying reclassification must be to Category 1 of the Bulk Drug Substances List or an equivalent classification that allows interim compounding of the drug. Removal from a different category will not qualify.
The resolution source for this market will be official statements from the FDA; however, a consensus of credible reporting will also be used.The July 2026 Pharmacy Compounding Advisory Committee meeting produced the most recent catalyst, with panel members voting 8-6 (one abstention) to recommend BPC-157 for the Section 503A Bulks List despite FDA staff opposition citing immunogenicity and impurity concerns. This non-binding advisory step followed the peptide’s earlier removal from Category 2 restrictions and occurs under current HHS leadership. Final FDA action on formal Category 1 placement remains pending, creating the core uncertainty reflected in trader pricing. Resolution hinges on whether the agency accepts the recommendation and issues the corresponding update to compounding eligibility lists, with any timeline tied to agency rulemaking procedures. Historical patterns show advisory votes are sometimes followed but can be overridden on safety grounds.
This market will resolve to “Yes” if the Food and Drug Administration (FDA) announces that it has reclassified or will reclassify BPC-157 to Category 1 of the Bulk Drug Substances List by the listed date, 11:59 PM ET. Otherwise, this market will resolve to “No”.
A qualifying announcement must be official and public. Any rumored or private statements of intention will not qualify.
Any announcement that the drug has been reclassified to Category 1 will qualify. Any announcement within this market’s timeframe of future intention to reclassify to Category 1 will qualify regardless of whether the reclassification has happened by the listed date.
A qualifying reclassification must be to Category 1 of the Bulk Drug Substances List or an equivalent classification that allows interim compounding of the drug. Removal from a different category will not qualify.
The resolution source for this market will be official statements from the FDA; however, a consensus of credible reporting will also be used.
A qualifying announcement must be official and public. Any rumored or private statements of intention will not qualify.
Any announcement that the drug has been reclassified to Category 1 will qualify. Any announcement within this market’s timeframe of future intention to reclassify to Category 1 will qualify regardless of whether the reclassification has happened by the listed date.
A qualifying reclassification must be to Category 1 of the Bulk Drug Substances List or an equivalent classification that allows interim compounding of the drug. Removal from a different category will not qualify.
The resolution source for this market will be official statements from the FDA; however, a consensus of credible reporting will also be used.
Volumen
$2,565Fecha de finalización
31 dic 2026Mercado abierto
Jun 22, 2026, 10:10 PM ETResolver
0x65070BE91...The July 2026 Pharmacy Compounding Advisory Committee meeting produced the most recent catalyst, with panel members voting 8-6 (one abstention) to recommend BPC-157 for the Section 503A Bulks List despite FDA staff opposition citing immunogenicity and impurity concerns. This non-binding advisory step followed the peptide’s earlier removal from Category 2 restrictions and occurs under current HHS leadership. Final FDA action on formal Category 1 placement remains pending, creating the core uncertainty reflected in trader pricing. Resolution hinges on whether the agency accepts the recommendation and issues the corresponding update to compounding eligibility lists, with any timeline tied to agency rulemaking procedures. Historical patterns show advisory votes are sometimes followed but can be overridden on safety grounds.
Resumen experimental generado por IA con datos de Polymarket. Esto no es asesoramiento de trading y no influye en cómo se resuelve este mercado. · Actualizado
Cuidado con los enlaces externos.
Cuidado con los enlaces externos.
Preguntas frecuentes